Zai Lab (NASDAQ:ZLAB) Director Sells $127,353.60 in Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Get Free Report) Director William Lis sold 7,040 shares of Zai Lab stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $18.09, for a total transaction of $127,353.60. Following the sale, the director owned 50,437 shares of the company’s stock, valued at $912,405.33. The trade was a 12.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Zai Lab Price Performance

Zai Lab stock opened at $18.00 on Friday. The stock has a market cap of $2.04 billion, a price-to-earnings ratio of -11.11 and a beta of 0.78. The firm has a 50-day moving average of $19.40 and a two-hundred day moving average of $18.96. Zai Lab Limited Unsponsored ADR has a 1 year low of $15.96 and a 1 year high of $41.20.

Get Zai Lab alerts:

Zai Lab (NASDAQ:ZLAB – Get Free Report) last issued its earnings results on Wednesday, April 1st. The company reported ($0.50) EPS for the quarter. Zai Lab had a negative return on equity of 24.32% and a negative net margin of 39.29%.The company had revenue of $99.61 million for the quarter. Research analysts expect that Zai Lab Limited Unsponsored ADR will post -2.23 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Citigroup decreased their target price on Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Wall Street Zen lowered shares of Zai Lab from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Cantor Fitzgerald reduced their price target on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating for the company in a report on Friday, February 27th. JPMorgan Chase & Co. lowered their price target on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating for the company in a research report on Wednesday, March 18th. Finally, Weiss Ratings downgraded shares of Zai Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 4th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, Zai Lab has an average rating of “Moderate Buy” and an average target price of $45.83.

Read Our Latest Stock Report on ZLAB

Institutional Trading of Zai Lab

An institutional investor recently raised its stake in Zai Lab stock. Royal Bank of Canada increased its position in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Free Report) by 214.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,771 shares of the company’s stock after acquiring an additional 9,390 shares during the quarter. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 as of its most recent SEC filing. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Zai Lab Company Profile

(Get Free Report)

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.

Featured Stories

• Five stocks we like better than Zai Lab
• Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
• AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
• Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
• Xcel Energy Stock Offers Stability as Electricity Demand Builds

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.